# Dulaglutide

## Trulicity inj 1.5mg/0.5mL

| TAH Drug Code      | [ITRUL](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITRUL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Type 2 diabetes mellitus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | This product is a single dose of 1.5mg, and the dose cannot be adjusted. Initial, 0.75 mg once weekly; may increase to 1.5 mg once weekly for additional glycemic control; The maximum dose: 1.5 mg once weekly.                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Contraindications  | Hypersensitivity to dulaglutide or any of its components. Multiple endocrine neoplasia syndrome type 2 or personal or family history of medullary thyroid carcinoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common Gastrointestinal: Abdominal pain (6.5% to 9.4% ), Decrease in appetite (4.9% to 8.6% ), Diarrhea (7% to 12.6% ), Nausea (12.4% to 21.1% ), Vomiting (5.6% to 12.7% ) Serious Cardiovascular: Atrioventricular block, First degree (1.7% to 2.3% ) Endocrine metabolic: C-cell hyperplasia of thyroid, Hypoglycemia (0.3% to 77% ), Thyroid cancer Gastrointestinal: Cholecystitis, Cholelithiasis, Pancreatitis Immunologic: Anaphylaxis, Hypersensitivity reaction, Systemic (0.5% ) Ophthalmic: Retinopathy due to diabetes mellitus (1.9% ) Renal: Acute renal failure, Chronic renal failure, Exacerbation Other: Angioedema |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

